A Phase I Study of HMPL-306 in Myeloid Leukemia/Neoplasms
Condition: Acute Myeloid Leukemia Intervention: Drug: HMPL-306 Sponsor: Hutchison Medipharma Limited Not yet recruiting
Contributors : Ling Li ; Xin HeSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe want to obtain FLT3-ITD gene signature. To do so, we transduced CB CD34+ cells with mock or FLT3-ITD vectors and performed RNA sequencing (RNA-Seq).Two Groups: Group1: CB CD34+ cells transduced with mock vector; Group2: CB CD34+ cells transduced with FLT3-ITD vector;
Contributors : Elizabeth Ostrander ; Grant A ChallenSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusEpigenetic modifying enzymes DNMT3A and TET2 are recurrently mutated in hematological disorders despite possessing opposing biochemical functions in the DNA methylation processes. Using conditional ablation, we show these contrasting genotypes result in different functional effects in hematopoietic stem cells (HSCs). Loss of Dnmt3a bestows enhanced self-renewal on HSCs in serial, competitive repopulation assays while Tet...
Publication date: Available online 31 March 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Nada Alhazmi, Chun-Peng Pai, Aljawharah Albaqami, Han Wang, Xuan Zhao, Minyue Chen, Po Hu, Shuang Guo, Kyle Starost, Omid Hajihassani, Masaru Miyagi, Hung-Ying Kao
Conditions: Acute Leukemia; Myelodysplastic Syndromes Intervention: Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells Sponsor: Edwin Horwitz Not yet recruiting
A new combination of old drugs has shown'unexpectedly'higher response rates in patients with relapsed/refractory acute myeloid leukemia.Medscape Medical News
Publication date: Available online 30 March 2020Source: The Veterinary JournalAuthor(s): Y.C. Chen, C.C. Chang, W.L. Hsu, S.T. Chuang
(Children's Hospital Los Angeles) In a preclinical study, scientists engineer new CAR-T cells to attack three sites on leukemia cells, instead of one. The new cells are more effective at killing the cancer.
Schematics of the experimental protocol used to demonstrate the selective anti ‐tumor effect of the OSKM factors in vivo. Briefly, HSPCs from reprogrammable mice were isolated, infected in culture for 2 days with a retrovirus containing MLL‐AF9‐GFP and transplanted into sublethally irradiated mice. One week later the percentage of GFP+ cells in the bone marrow and bloo d was determined and animals treated with doxycycline (doxy) for 1 week to activate OSKM in the donor cells or left untreated (no doxy). The mice were then monitored for several months for the onset of leukemia and death. While untreated animals...
A simple and cost-effective intervention led to reductions in CT radiation...Read more on AuntMinnie.comRelated Reading: Report: Medical radiation dose plummets 20% Low-dose CT produces no detectable DNA damage CT radiation increases risk of thyroid cancer, leukemia Radiologist leadership cuts CT lung screening radiation New study links medical imaging radiation to cancer risk
Condition: Cancer Intervention: Drug: PARP Inhibitors Sponsor: University Hospital, Caen Active, not recruiting